前瞻性应用肝脏影像报告和数据系统(LI-RADS)在钆塞酸增强MRI中的诊断准确性
回顾性分析143例未治疗高危患者钆塞酸增强MRI前瞻性报告的202个肝脏病灶,按LI-RADS v2014分类。LR-5/5V诊断HCC特异度97.3%、敏感度60.5%;纳入LR-M后敏感度升至68.2%(p=0.002),特异度降至93.2%(p=0.154)。LR-5/5V/M诊断肝脏恶性肿瘤敏感度68.9%、特异度100.0%。
要点
- LR-5/5V对HCC高度特异(97.3%),但敏感度仅60.5%。
- 多数LR-M病灶最终为HCC(13例中10例,76.9%)。
- 近半数非HCC恶性肿瘤被归为LR-4或LR-5。
核心结论
- LI-RADS v2014可成功用于钆塞酸增强MRI临床实践;LR-5/5V是HCC最特异的诊断指标,但多数LR-M为HCC,且相当部分非HCC恶性肿瘤被归为LR-4或LR-5。
研究设计与样本
- 回顾性分析2014年1月至12月143例未治疗高危患者的前瞻性钆塞酸增强肝脏MRI报告,共202个肝脏病灶按LI-RADS v2014分类。
关键影像表现/征象
- 29个LR-4中20个(69.0%)为HCC,75个LR-5中73个(97.3%)为HCC,5个LR-5V全部(100%)为HCC。
- 2个(2.7%)LR-5最终为混合型肝细胞-胆管细胞癌。
- 13个LR-M中10个(76.9%)为HCC。
诊断标准与关键数值
- LR-5/5V诊断HCC的敏感度60.5%、特异度97.3%。
- 将LR-M纳入HCC诊断标准后敏感度升至68.2%(p=0.002),特异度降至93.2%(p=0.154,无统计学显著性)。
- LR-5/5V/M诊断肝脏恶性肿瘤的敏感度68.9%、特异度100.0%。
临床应用与阅片要点
- LR-5/5V可提供HCC的高度特异诊断。
- LR-5/5V/M在钆塞酸增强MRI上可实现更敏感的HCC诊断。
- LR-5/5V或LR-M类病灶均为明确恶性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the diagnostic performance of the LI-RADS (v2014) on gadoxetate-enhanced MRI prospectively applied in actual practice.
METHODS: We retrospectively reviewed the prospectively written radiology reports of 143 treatment-naïve at-risk patients who underwent gadoxetate-enhanced liver MRI from January to December 2014, and identified 202 hepatic observations categorized using the LI-RADS. The diagnostic performances of LI-RADS categories for hepatocellular carcinoma (HCC) and hepatic malignancy were calculated.
RESULTS: Twenty (69.0 %) of 29 LR-4, 73 (97.3 %) of 75 LR-5, and all of five (100 %) LR-5V observations were HCCs. The remaining two (2.7 %) LR-5 observations were combined hepatocellular-cholangiocarcinomas, while 10 (76.9 %) of 13 LR-M observations were HCCs. The sensitivity and specificity of LR-5/5V for HCC were 60.5 % and 97.3 %, respectively. Including LR-M in the diagnostic criteria for HCC increased sensitivity (68.2 %, p = 0.002) but decreased specificity without statistical significance (93.2 %, p = 0.154). LR-5/5V/M yielded sensitivity of 68.9 % and specificity of 100.0 % for hepatic malignancy.
CONCLUSIONS: LI-RADS v2014 was successfully applied on gadoxetate-enhanced MRI in clinical practice. LR-5/5V was the most specific diagnostic measure for HCC, but most LR-M observations were HCCs and a considerable portion of non-HCC malignancies were categorized as LR-4 or LR-5.
KEY POINTS: • LR-5/5V provided a highly specific diagnosis for HCC. • Half of non-HCC malignancies were categorized as LR-4 or LR-5. • The majority of LR-M observations were finally diagnosed as HCCs. • More sensitive diagnosis of HCC was feasible with LR-5/5V/M on gadoxetate-enhanced MRI. • Observations in either LR-5/5V or LR-M categories were definitely malignant.
引用
- Kim YY, An C, Kim S, et al. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol. 2017. PMID: 29230525. doi:10.1007/s00330-017-5188-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。